Merck revealed on 4 September its investigational beta-lactamase inhibitor relebactam (MK-7655) was dubbed a qualified infectious disease product (QIDP) by the FDA.
As a QIDP-designated medicine – a status the FDA has granted at least 52 times to 35 unique molecular entities...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
